search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


GLUCOVAS.


- candidate number6005
- NTR NumberNTR1874
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR22-jun-2009
- Secondary IDs08/382 METC AMC
- Public TitleGLUCOVAS.
- Scientific TitleGlucose regulation by continuous tube feeding and Vildagliptin in addition to insulin in hyperglycemic acute stroke patients.
- ACRONYMGLUCOVAS
- hypothesis1. TGC with insulin in continuous tube fed patients is superior to TGC with insulin in regularly fed patients;
2. Vildagliptin as add-on therapy to insulin mediated TGC results in less hypoglycemic episodes compared to placebo.
- Healt Condition(s) or Problem(s) studiedHyperglycemia, Acute ischemic stroke
- Inclusion criteria1. Supra-tentorial stroke with a time of onset within 24h before presentation;
2. An acute neurological deficit measurable with the National Institute of Health Stroke Score (see appendix I, NIHSS score) 4 at presentation;
3. Venous plasma admission glucose > 7.0 mmol/l;
4. Informed consent.
- Exclusion criteria1. Signs of cerebral hemorrhage on computed tomography scan;
2. Previous history of diabetes mellitus treated with insulin;
3. Patients in whom death appears imminent;
4. Renal insufficiency defined as creatinine > 150 mmol/L;
5. Patients under the age of 18;
6. Pregnant patients;
7. Expected transfer to a different hospital within 5 days.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingSingle
- controlPlacebo
- groupFactorial
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 10-jul-2009
- planned closingdate10-aug-2009
- Target number of participants30
- Interventions1. IV insulin;
2. Continuous tube feeding;
3. Vildagliptin.
- Primary outcome1. Glycemic control. (Mean glucose throughout protocol treatment; Percentage of time spent within target range);
2. Hypoglycemia (glucose <3.5 mmol/L): Number of hypoglycemic events per group, Number of serious hypoglycemic events (glucose<2.2 mmol/L), Number of symptomatic confirmed hypoglycemic events.
- Secondary outcome1. Clinical outcome (modified Rankin score) at three months;
2. Incidence of pneumonia;
3. Treatment data.
- Timepoints1. 5 days;
2. 3 months.
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIESMD Nyika Kruyt
- CONTACT for SCIENTIFIC QUERIESMD Nyika Kruyt
- Sponsor/Initiator Academic Medical Center (AMC), Amsterdam
- Funding
(Source(s) of Monetary or Material Support)
Novartis
- PublicationsN/A
- Brief summaryHyperglycemia has been associated with poor clincal outcome in patients with acute ischemic stroke. Therefore, glycemic control has the potential to improve clinical outcome. Glycemic control, however, appears to be difficult to establish due to postprandial glucose surges and an increased number of hypoglycemic episodes. With this study we investigate if (i) glycemic control in continuous tube fed patients is superior compared to regularly fed patients and (ii) If vildagliptin as add-on therapy to insulin results in less hypoglycemic episodes compared to placebo.
- Main changes (audit trail)
- RECORD22-jun-2009 - 6-okt-2009


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl